Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Leukemia

Volumn 25, Issue 10, 2011, Pages 1657-1661

  Kroger N ^a   Zabelina, T ^a   Berger, J ^a   Duske, H ^a   Klyuchnikov, E ^a   Binder, T ^a   Stubig T ^a   Hilde Brandt, Y ^a   Atanackovic, D ^a   Alchalby, H ^a   Ayuk, F ^a   Zander, A R ^a   Bacher, U ^a   Eiermann, T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; MELPHALAN; THYMOCYTE ANTIBODY; TREOSULFAN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; FEMALE; GENDER; GENE DELETION; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRRADIATION; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

EID: 80054016181     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.138     Document Type: Letter

References (8)

1. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588-3594. (Pubitemid 46572554)
2. Ruggeri L, Capanni M, Urbani E, Perruccio K, ShlomchikWD, Tosti A et al. Effectiveness if donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097.
3. Kröger N, Shaw B, Iacobelle S, Zabelina T, Peggs K, Shimoni A et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 2005; 129: 631-643. (Pubitemid 40825825)
4. Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improve disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006; 82: 1024-1030. (Pubitemid 44632116)
5. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT et al. Donors with group B KIR haplotypes improve relapsefree survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113: 726-732.
6. Uhrberg M, Parham P, Werner P. Definition of gene content for nine common group B haplotypes of the caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 2002; 54: 221.
7. Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B et al. Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood 2010; 115: 3162-3165.
8. Gahrton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Blade J et al. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant 2005; 35: 609-617. (Pubitemid 40450461)